Vanja de Weerd

Vanja de Weerd

UNVERIFIED PROFILE

Are you Vanja de Weerd?   Register this Author

Register author
Vanja de Weerd

Vanja de Weerd

Publications by authors named "Vanja de Weerd"

Are you Vanja de Weerd?   Register this Author

27Publications

912Reads

13Profile Views

Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer.

Cancers (Basel) 2019 Jul 27;11(8). Epub 2019 Jul 27.

Department of Pathology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11081062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721358PMC
July 2019

Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.

Am J Pathol 2017 Jul;187(7):1648-1655

Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2017.03.012DOI Listing
July 2017

mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.

Mol Oncol 2015 Apr 21;9(4):920-32. Epub 2015 Jan 21.

Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528769PMC
April 2015

Integrative analysis of genomics and proteomics data on clinical breast cancer tissue specimens extracted with acid guanidinium thiocyanate-phenol-chloroform.

J Proteome Res 2015 Mar 2;14(3):1627-36. Epub 2015 Feb 2.

Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam , Be401, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jproteome.5b00046DOI Listing
March 2015

DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells.

Breast Cancer Res Treat 2015 Feb 8;149(3):693-703. Epub 2015 Feb 8.

Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB, Nijmegen, The Netherlands,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3281-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326655PMC
February 2015

Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.

Breast Cancer Res Treat 2012 Jun 12;133(3):843-51. Epub 2011 Jul 12.

Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus MC, Building BE, Room 400, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1663-3DOI Listing
June 2012

Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.

Breast Cancer Res Treat 2012 Apr 26;132(2):439-48. Epub 2011 May 26.

Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1588-xDOI Listing
April 2012

Hormone replacement therapy dependent changes in breast cancer-related gene expression in breast tissue of healthy postmenopausal women.

Mol Oncol 2011 Dec 16;5(6):504-16. Epub 2011 Sep 16.

Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2011.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528323PMC
December 2011

Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.

Breast Cancer Res 2010 1;12(6):R103. Epub 2010 Dec 1.

Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, GE, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2786DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046448PMC
September 2011

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.

Breast Cancer Res Treat 2011 May 19;127(1):43-51. Epub 2010 May 19.

Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr. Molewaterplein 50, Be 4.02 (lab)/4.35b (office), PO Box 2040, 3000 CA Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-0940-xDOI Listing
May 2011

Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.

Proc Natl Acad Sci U S A 2008 Sep 28;105(35):13021-6. Epub 2008 Aug 28.

Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0803304105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529088PMC
September 2008